AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03835572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CircaHealth: a course on circadian rhythms and health
Description: Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
Study NCT03835572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene materials
Description: Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
Study NCT04273061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg by intravenous infusion every 3 weeks as tolerated
Study NCT03651544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GamFluVac
Description: 1 dose (0,5 ml)
Study NCT00684099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
Study NCT00684099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
Study NCT01543958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
Study NCT01543958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Study NCT02649270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T1h
Description: Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
Study NCT03286088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MitraClip
Description: imaging as standard practice
Study NCT02245568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMTM
Description: The initial LMTM dose was 200 mg/day (one 100-mg tablet twice daily), except in subjects with bvFTD who were taking a reduced dose (i.e., 100 mg/day) upon entering this extension study. The dose could be increased (after at least 13 weeks of treatment) or decreased (at any time at or after 2 weeks of treatment) by the Investigator in 100-mg increments or decrements. The maximum allowable dose was 300 mg/day (or in those countries where limited by a Competent Authority or Ethics Committee, 200 mg/day).
Study NCT02037802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-Braun, Perifix® ONE Paed, Germany
Description: caudal epidural catheterization bupivacaine fentanyl
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pethidine
Description: pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
Study NCT01532739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: fentanyl propofol atracurium besylate
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: fentanyl propofol atracurium besylate
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT02037802 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fentanyl
Study NCT02347241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational Debriefings and High frequency training and team reflection
Study NCT02849990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT03164109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4419 IV
Description: 50mg infused IV over 15 minutes
Study NCT03164109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infused IV over 15 minutes
Study NCT03164109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral moxifloxacin
Description: 400 mg tablet orally with 250 mL room temperature water
Study NCT05665517 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot Little K Nurse
Description: The CKD chat-based instant messaging support health education system in this study was named Chatbot Little K Nurse and connected to the Line platform to set up a one-to-one line. K stands for kidney. Each group contained three parties: patients with CKD (participants ), Chatbot Little K Nurse (virtual), and an instructor (health teacher) for an enhanced intervention. According to the handbook of CKD health management by the Health Promotion Administration (2018b) and the CKD Clinical Diagnosis and Treatment Guidelines for literature investigation in Taiwan, 350 groups of question-and-answer (Q\&A) corpora were formed.
Study NCT01144403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: as prescribed, 6 cycles
Study NCT01144403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: as prescribed, 6 cycles
Study NCT01144403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: as prescribed, 6 cycles
Study NCT01144403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
Study NCT01684527 — intervention group
Intervention type: OTHER
Intervention: Respiratory secretions obtained
Study NCT01625507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PANDA intervention
Description: Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
Study NCT03553563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H capsule 10mg
Description: All Groups can select either capsule or sachet during the study.
Study NCT03553563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D961H sachet 10mg
Description: All Groups can select either capsule or sachet during the study.
Study NCT00508027 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin
Description: Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
Study NCT02617641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAVIEenM@RCHE
Description: The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
Study NCT02617641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Publicly available websites
Description: * Le Programme de marche (Institut de Cardiologie de Montréal)~* L'activité physique (Institut de Cardiologie de Montréal)~* L'activité physique (Fondation des maladies du cœur et de l'AVC)~* Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~* Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)
Study NCT04657250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation + quitline linkage text messages
Description: Smoking cessation text messages will provide behavioral skills and support for quitting smoking. Quitline linkage text messages will include contact information for the quitline, option to be contacted by the quitline and active referral to the quitline upon setting a Quit Date.
Study NCT04657250 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passive quitline referral
Description: Single text message with contact information for the Quitline
Study NCT00604084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
Study NCT00604084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin 5% lotion
Description: apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
Study NCT01185379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Efalex active 50+
Description: 4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
Study NCT01185379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA rich fish oil
Description: 4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
Study NCT01185379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 x 500 mg capsules to be taken daily for 6 months
Study NCT02971722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JY09
Description: 2mg/1ml/bottle
Study NCT02971722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml/bottle
Study NCT02946606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: Human growth hormone
Study NCT02946606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin
Description: Human growth hormone
Study NCT00628056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perhexiline
Description: Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
Study NCT00628056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perhexiline
Description: Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
Study NCT02849990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT02849990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Given SC
Study NCT03355053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dex (Precedex, Dexmedetomidine HCl Injection) is produced by Pfizer Inc, NY, Ny (formerly Hospira). Dex is a white or almost white powder that is freely soluble in water and has a pKa of 7.1. Its partition coefficient in-octanol: water at pH 7.4 is 2.89. Dex is supplied as a clear, colorless, isotonic solution with a pH of 4.5 to 7.0. Each mL contains 118 mcg of dexmedetomidine hydrochloride equivalent to 100 mcg (0.1mg) of dexmedetomidine and 9 mg of sodium chloride in water. The solution is preservative-free and contains no additives or chemical stabilizers. The MGH Pharmacy currently obtains Dex from the supplier as a solution in 50 mL clear-glass bottles, as a clear liquid, at a concentration of 4mcg/mL.
Study NCT03355053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: From the package insert: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is produced by Pfizer Inc, NY, Ny (formerly Hospira). It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+ ) 154 mEq; chloride (Cl- ) 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH is 5.6 (4.5 to 7.0). This solution contains no bacteriostat, antimicrobial agent or added buffer and is intended only as a single-dose injection. When smaller doses are required, the unused portion should be discarded. 0.9% Sodium Chloride Injection, USP is a parenteral fluid and electrolyte replenisher. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H2O.
Study NCT02378116 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical closure of the left atrial appendage
Description: When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
Study NCT03906734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Septal myectomy
Description: Transaortic septal myectomy
Study NCT03906734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Septal myectomy
Description: Transaortic septal myectomy
Study NCT03906734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alfieri stich
Description: Transaortic Mitral valve repair using alfieri technique
Study NCT03906734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subvalvular intervention
Description: Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
Study NCT03245060 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adapted Solution Focused Brief Therapy
Description: Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
Study NCT02849990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Given PO
Study NCT02849990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study
Study NCT02849990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02150187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HCap Formula
Description: Pill should be taken every other day during the treatment phase.
Study NCT02150187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar pills without active ingredients
Study NCT01252134 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution
Study NCT01252134 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution
Study NCT02063087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head CT Decision Aid
Description: The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
Study NCT02340689 — intervention group
Intervention type: OTHER
Intervention: Genetic Analysis
Description: We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
Study NCT01252134 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution
Study NCT01252134 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses
Study NCT03135587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loading level
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
Study NCT01471834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO System
Study NCT01471834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management
Study NCT00172068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid + Calcium/Vitamin D
Study NCT00172068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid + Calcium/Vitamin D
Study NCT03245060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Solution Focused Brief Therapy
Description: Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
Study NCT04163471 — intervention group
Intervention type: DEVICE
Intervention: Radial artery mechanical compression for hemostasis
Description: Transradial hemostasis following arterial catheterization procedures
Study NCT03091712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glooko Mobile Insulin Dosing System(MIDS)
Description: Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
Study NCT04013074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic Shunt
Description: Transjugular Intrahepatic Portosystemic Shunt
Study NCT04013074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
Study NCT04013074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
Study NCT00111566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptifibatide
Study NCT00111566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptifibatide
Study NCT00749411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT00749411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705/GW642444
Description: The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
Study NCT00426530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus (RAD001)
Study NCT00651287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinapril 20 mg
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
Study NCT00651287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinapril 20 mg plus hydrochlorothiazide 12.5 mg
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
Study NCT00651287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinapril 40 mg
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
Study NCT03690245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initiation of Resuscitation While Attached to the Cord
Description: Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.